Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Allogeneic T Cell Therapies Market Outlook

The global allogeneic T cell therapies market size is anticipated to grow at a CAGR of 9.75% during the forecast period of 2024-2032, driven by the rising prevalence of cancer cases across the globe.

Allogeneic T Cell Therapies: Introduction

Allogeneic or universal cell therapies rely on a single source of cells to treat patients. Cells are collected from a healthy person’s body and directly transferred into the patient’s body or developed into a master cell bank (MCB). There are several advantages of using allogenic treatments and one of them is easy availability of cells and tissues. However, allogeneic treatments may also be responsible for transmitting infections or diseases. The use of allogeneic cell therapy is majorly performed in patients whose own stems cells cannot be transplanted, such as people suffering from leukemia.

Global Allogeneic T Cell Therapies Market Analysis

The prevalence of chronic diseases like cancer has been increasing rapidly owing to the unhealthy lifestyles and carcinogenic environment, among other factors. The awareness about the importance of getting a timely treatment for cancer is also growing among the population. This has increased the need for advanced and efficient treatments and therapies, including allogeneic T cell therapies. With the rising number of patients opting for timely treatments owing to the advanced diagnostic tests and treatments available for cancer, the demand for allogeneic T cell therapies is likely to grow further in the coming years. Allogeneic T cell therapies have gained significant popularity among oncologists as they offer efficient benefits to the patient in fighting the cancer cells.

Governments of several countries are taking initiatives to improve their healthcare systems in order to provide the best treatment to the patients with an overall enhanced patient experience. The increasing number of research and development activities for allogeneic T-cell therapy significantly adds to the global allogeneic T cell therapy market growth. Recent research has exhibited the advancement of Chimeric antigen receptor (CAR) T cell therapy, which was previously used for treating blood cancers like leukemia, lymphoma, and multiple myeloma. It has now shown effective action against solid tumours from lung cancer to kidney cancer to bone cancer as well.

The increasing number of approvals is also influencing the market growth. For example, six CAR T cell therapies that demonstrated efficacy in patients with B-cell malignancies and multiple myeloma, which was never seen before, have been approved officially. Additionally, the increasing investment by pharmaceutical companies are also likely to add significantly to the global allogeneic T cell therapy market share.

The increasing collaborations among the key players are also aiding the growth of the market. For instance, a collaboration between HaemaLogiX and Peter MacCallum Cancer Centre took place in August 2024, which is expected to result in the advancement of KMA, Kappa Myeloma Antigen, which is a receptor solely appearing on myeloma cells in kappa-type MM.

Global Allogeneic T Cell Therapies Market Segmentations

Market Breakup by Product Type

  • Chimeric Antigen Receptor (CAR) T Cell Therapies
  • T Cell Receptor (TCR) Therapies
  • Others

Market Breakup by Therapeutics Indications

  • Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Others

Market Breakup by End User

  • Hospitals
  • Specialty Clinics
  • Research Institutes
  • Others

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global Allogeneic T Cell Therapies Market Overview

The growth of the global market for allogeneic T cell therapy is driven by the rising accessibility of gene therapies in the market. The growth is also driven by the rising geriatric and paediatric patient population, and the increasing prevalence of chronic diseases, such as cancer. The rising awareness about gene cell therapies and its benefits are further aiding the market demand. Due to the increasing awareness, the demand for effective gene and cell treatment therapies is also increasing, further propelling the global allogeneic T cell therapy market value. The expenditure against T cell therapies is also rising, which is likely to provide further impetus to the growth of the market.

Allogeneic T Cell Therapies Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

  • Athersys Inc. 
  • Mesoblast Ltd.
  • Biorestorative Therapies Inc.
  • Pluristem Inc.
  • Brainstorm Cell Limited.
  • ViaCyte Inc.
  • Gamida Cell
  • HOPE BIOSCIENCES
  • Cellular Biomedicine Group 
  • Smith+Nephew 
  • MEDIPOST 
  • ANTEROGEN.CO, LTD. 
  • NuVasive Inc. 
  • RTI Surgical 
  • AlloSource 
  • JCR Pharmaceuticals Co. Ltd. 
  • Takeda Pharmaceutical Company Limited

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product Type
  • Therapeutics Indications
  • End User
  • Region
Breakup by Prodcut Type
  • Chimeric Antigen Receptor (CAR) T Cell Therapies 
  • T Cell Receptor (TCR) Therapies 
  • Others
Breakup by Therapeutics Indications
  • Cancer
  • Autoimmune Diseases
  • Infectious Diseases 
  • Others
Breakup by End User
  • Hospitals
  • Specialty Clinics
  • Research Institutes
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Athersys Inc. 
  • Mesoblast Ltd.
  • Biorestorative Therapies Inc.
  • Pluristem Inc.
  • Brainstorm Cell Limited.
  • ViaCyte Inc.
  • Gamida Cell
  • HOPE BIOSCIENCES
  • Cellular Biomedicine Group 
  • Smith+Nephew 
  • MEDIPOST 
  • ANTEROGEN.CO, LTD. 
  • NuVasive Inc. 
  • RTI Surgical 
  • AlloSource 
  • JCR Pharmaceuticals Co. Ltd. 
  • Takeda Pharmaceutical Company Limited

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The market is anticipated to grow at a CAGR of 9.75% during the forecast period of 2024-2032.

The rising awareness and demand for cell therapies in the market are among the major factors driving the market growth.

The increasing number of research and development activities and increasing collaborations between companies to develop more effective cell therapies are among major trends influencing the market growth.

The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.

The products available in the market include chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) therapies, among others.

Different therapeutic indications include cancer, autoimmune diseases, and infectious diseases, among others.

The end users in the market include hospitals, specialty clinics, and research institutes, among others.

Key players involved in the market are Athersys Inc., Mesoblast Ltd., Biorestorative Therapies Inc., Pluristem Inc., Brainstorm Cell Limited., ViaCyte Inc., Gamida Cell, HOPE BIOSCIENCES, Cellular Biomedicine Group, Smith+Nephew, MEDIPOST, ANTEROGEN.CO, LTD., NuVasive Inc., RTI Surgical, AlloSource, JCR Pharmaceuticals Co. Ltd., and Takeda Pharmaceutical Company Limited.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124